21st
January 2019 - The
enzyme inhibitor market is expected to witness growth owing to the growth of
pharmaceutical drug industry. The key driver of this industry is the global
spending on medicines in coalition with the increasing demand of specialty
drugs. The North American region is accounted for more than 40% market share
mainly due to the presence of leading players in US pharmaceutical industry.
The Asia Pacific region is projected to see highest growth rate by 2022,
particularly China is expected to witness more than 15% CAGR in the forecasted
period.
Enzyme inhibitor is a molecule which particularly binds with an enzyme to
slow down its activity. It is primarily used to kill a pathogen, which produces
harmful diseases to maintain the metabolic imbalance. In Agricultural industry,
it is mainly used as a pesticide to attract and destroy any pest. There are
many applications of enzyme inhibitor such as chemotherapy, metabolic control,
pesticides, and natural poisons. These inhibitors alter the functioning of
enzymes and thus altering the gene expression. Few other important applications
such as male erectile dysfunction, survival of bacterial pathogens, blocking
specific protein in the pancreas, regulation of neurological functioning, and stopping
toxins that pollutes environment are expected to drive the market in the near
future.
Browse
Full Research Report @ https://www.millioninsights.com/industry-reports/enzyme-inhibitor-market
Few factors that are expected to thrust the market of enzyme inhibitor
are research & development spending by pharmaceutical companies, increasing
competition, and technological advancement. Upcoming new technologies have led
to the new product development, which has assisted the market to expect high
growth over the forecasted period. Sedentary lifestyle, pandemic threats, and
higher risk of disease are few other driving factors that will fuel in the
growth of the market by 2022. The key restrain that may slightly decrease the
revenue growth of the market is due to the patent expiration. Last few years
patent expiration has led the pharmaceutical industry to bear revenue losses of
more than USD 20 billion each year, but from the strategic actions by
pharmaceutical companies it is projected to go down to less than one third.
The market is segmented by reversible and irreversible as per the
inhibitors binding with the enzymes. Reversible inhibitor binding with enzyme
is created through non-covalent bonding such as ionic bonds or hydrogen bonds.
Non-reversible inhibitor binding with enzyme is created through covalent
bonding by reacting chemically with the enzyme.
The market segmentation by inhibitor type into proton pump inhibitors
(PPI), phosphodiesterase type 5 (PDE5) inhibitors, protease inhibitors,
neuraminidase inhibitors, aromatase inhibitors, reverse transcriptase
inhibitor, statins, kinase inhibitors, and angiotensin-converting enzyme (ACE)
inhibitors. These inhibitors have varied application in the pharmaceutical
industry on the basis of reaction with the pathogens such as PPIs for reducing
the long lasting production of gastric acid, PDE5 to treat the erectile
dysfunction, protease for the treatment of HIV/AIDS, kinase to block the action
of protein kinases, reverse transcriptase to generate complementary DNA,
neuraminidase to block the influenza virus, statins for reducing the
cholesterol production, and angiotensin for the treatment of hypertension.
The market can also be segmented by region into North America, Latin
America, Europe, Asia Pacific, and Middle East. Globally, the North America has
the highest market share due to the presence of largest players who produces
the enzyme inhibitor drugs. Particularly the US has the top five largest
pharmaceutical companies based on the revenue share. In totality, it has more
than 150 companies, which are competing in the enzyme inhibitor market. Research
& development spending in the US is highest among other countries of North
American region.
The European region has the second highest market share of enzyme
inhibitor drugs mainly due to the high government expenditure towards
pharmaceutical industries and companies involvement in producing the drug.
Particularly in the United Kingdom, there are companies such as GlaxoSmithKline
and AstraZeneca, which accounts for maximum revenue market share of enzyme
inhibitor drugs.
The Asia Pacific region is the fastest growing market mainly due to the
increasing awareness of inhibitor drugs and increasing investment from foreign
companies. Particularly the countries such as India, China, Japan, Russia, and
Singapore accounts for more than half of the market share among other countries
in the region. This is due to the high economic development, higher
investments, increasing awareness, and high population. In the forecasted
period, the Asia pacific region is expected to account for maximum share
globally in at least 4-5 inhibitor drugs.
The key players that compete in the enzyme inhibitor market are Novartis,
Pfizer, Roche, Sanofi, Merch & Co., Johnson & Johnson, GlaxoSmithKline,
AstraZeneca, Gilead Sciences, Takeda, Bayer, Astellas, Daiichi Sankyo, Baxter
and Novo Nordisk. Out of these companies, Novartis and Pfizer accounts for
highest revenue market share and highest R&D spending.
Request
a Free Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/enzyme-inhibitor-market/request-sample
Comments
Post a Comment